- Balchem delivered a good set of results for 3Q 2020, with revenue and pre-tax profit up +10.4% and +14.2% YoY, respectively.
- The potential FDA approval for an autism drug referred to as CM-AT in a few years' time could be a positive re-rating catalyst for Balchem in the medium term.
- The company also continues to strike a balance between M&A and other capital allocation options.
- Balchem trades at consensus forward FY 2021 and FY 2022 P/E of 41.3 times and 37.6 times, respectively.
For further details see:
Balchem: Spotlight On Pandemic Tailwinds And Autism Drug